Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors

Table 2 Multivariate analysis of risk factors for DSP and symptomatic DSP in the ritonavir/lopinavir-group

	Univariate analysis		Multivariate analysis
	Odds ratio (95 % CI)	P value	Odds ratio (95 % CI)	P value
DSP
Age >36 years
Yes	3.9 (1.26–12.08)	0.018	7.0 (0.88–55.65)	0.08
No	1
BMI < 30 kg/m²
Yes	6.19 (1.56–24.47)	0.009	0.38 (0.03–5.37)	0.47
No	1
Waist circumference increased^a
Yes	0.18 (0.54–0.60)	0.005	1.33 (0.11–15.5)	0.82
No	1
Current CD4 count <250 cells/μL
Yes	5.88 (0.73–47.58)	0.09	0.43 (0.03–6.20)	0.54
No	1
Symptomatic DSP
Age >36 years
Yes	4.38 (1.32–14.50)	0.016	7.39 (1.07–50.77)	0.042
No	1
BMI <30 kg/m²
Yes	4.14 (1.00–17.05)	0.049	0.38 (0.03–5.62)	0.38
No	1
Waist circumference increased^a
Yes	0.23 (0.06–0.81)	0.023	1.86 (0.12–29.60)	0.66
No	1

DSP distal sensory polyneuropathy, defined by the presence of ≥1 neuropathic sign, symptomatic DSP DSP in the presence ≥1 neuropathic symptom, BMI body mass index
^aDefined as a waist circumference of >88 cm for women and >102 cm for men

ISSN: 1742-6405